Lord’s Mark Industries Ltd. has achieved a significant milestone by receiving approval from the Central Licensing Authority in India for its LordsMed HIV 1&2 Self Test. This approval designates the company as the second in India and one of only nine globally to manufacture and export this Class D in-vitro diagnostic self-test, compliant with India's Medical Devices Rules, 2017. The product is intended exclusively for export markets, with sales commencing in June 2026, targeting key regions including Africa, the European Union, and South America, which are experiencing a shift towards decentralized, self-administered diagnostics. The global market for HIV self-testing is projected to grow to approximately $600–650 million by 2033, with a compound annual growth rate (CAGR) exceeding 13%. Africa, which bears the highest HIV burden, is expected to drive demand through donor-funded programs and public health initiatives. In addition, the EU and South America are witnessing increased adoption of self-testing kits, supported by government initiatives and expanding distribution channels. Sachidanand Upadhyay, Managing Director of Lord’s Mark, emphasized the importance of this approval for both the company and India's role in global healthcare, highlighting the commitment to quality and accessibility. The LordsMed HIV Self Test utilizes lateral flow immunoassay technology, allowing individuals to detect HIV-1 and HIV-2 antibodies from a finger-prick blood sample without laboratory infrastructure.